AI ASSISTANT

Ask DrugCentral

Explore drug properties, targets, and indications with answers grounded in DrugCentral.

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

AI can make mistakes. Verify answers against the original sources before relying on them.

Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
human origin	4958	477202-00-9

Description:

Molecule	Description
Synonyms: ipilimumab yervoy MDX-010 MDX-CTLA-4 ipilimumab (genetical recombination)	An anti-CTLA-4 ANTIGEN monoclonal antibody initially indicated for the treatment of certain types of metastatic MELANOMA. Its mode of actions may include blocking of CTLA-4 mediated inhibition of CYTOTOXIC T LYMPHOCYTES, allowing for more efficient destruction of target tumor cells. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

ipilimumab
yervoy
MDX-010
MDX-CTLA-4
ipilimumab (genetical recombination)

An anti-CTLA-4 ANTIGEN monoclonal antibody initially indicated for the treatment of certain types of metastatic MELANOMA. Its mode of actions may include blocking of CTLA-4 mediated inhibition of CYTOTOXIC T LYMPHOCYTES, allowing for more efficient destruction of target tumor cells.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
10	mg	P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company
July 3, 2015	PMDA	BRISTOL-MYERS SQUIBB K.K
March 25, 2011	FDA	BRISTOL MYERS SQUIBB
July 13, 2011	EMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	2361.17	22.18	984	28333	105886	90493244
Immune-mediated enterocolitis	1525.88	22.18	345	28972	4412	90594718
Hypophysitis	1380.53	22.18	284	29033	2236	90596894
Colitis	1178.09	22.18	533	28784	69409	90529721
Immune-mediated hepatitis	744.08	22.18	176	29141	2768	90596362
Death	645.86	22.18	764	28553	455787	90143343
Immune-mediated hepatic disorder	552.92	22.18	126	29191	1666	90597464
Adrenal insufficiency	547.60	22.18	242	29075	29679	90569451
Hypopituitarism	470.22	22.18	110	29207	1643	90597487
Hypothyroidism	459.07	22.18	258	29059	52869	90546261
Pneumonitis	452.25	22.18	240	29077	43930	90555200
Hyperthyroidism	430.75	22.18	177	29140	18133	90580997
Autoimmune colitis	420.94	22.18	87	29230	700	90598430
Immune-mediated lung disease	416.14	22.18	101	29216	1779	90597351
Thyroiditis	345.60	22.18	100	29217	3537	90595593
Immune-mediated dermatitis	333.70	22.18	74	29243	857	90598273
Autoimmune hepatitis	331.08	22.18	125	29192	10226	90588904
Fulminant type 1 diabetes mellitus	326.92	22.18	72	29245	806	90598324
Type 1 diabetes mellitus	326.34	22.18	102	29215	4710	90594420
Myocarditis	316.35	22.18	131	29186	13675	90585455
Immune-mediated hypophysitis	315.63	22.18	64	29253	463	90598667
Intentional product use issue	285.62	22.18	351	28966	216541	90382589
Immune-mediated thyroiditis	264.94	22.18	55	29262	453	90598677
Immune-mediated hypothyroidism	256.32	22.18	66	29251	1492	90597638
Immune-mediated myocarditis	251.89	22.18	63	29254	1262	90597868
Secondary adrenocortical insufficiency	248.38	22.18	70	29247	2248	90596882
Lymphocytic hypophysitis	243.88	22.18	47	29270	252	90598878
Enterocolitis	231.77	22.18	97	29220	10393	90588737
Diabetic ketoacidosis	222.87	22.18	123	29194	24284	90574846
Hepatic function abnormal	222.57	22.18	155	29162	46133	90552997
Diarrhoea	216.01	22.18	729	28588	938461	89660669
Adrenocorticotropic hormone deficiency	210.22	22.18	49	29268	719	90598411
Hepatitis	182.22	22.18	164	29153	70575	90528555
Immune-mediated encephalitis	177.77	22.18	40	29277	497	90598633
Immune-mediated uveitis	171.67	22.18	31	29286	108	90599022
Cytokine release syndrome	171.49	22.18	109	29208	27864	90571266
Pyrexia	165.06	22.18	528	28789	659957	89939173
Immune-mediated nephritis	160.84	22.18	36	29281	436	90598694
Metastatic malignant melanoma	160.29	22.18	46	29271	1578	90597552
Immune-mediated adrenal insuficiency	154.68	22.18	41	29276	1041	90598089
Metastases to central nervous system	140.11	22.18	81	29236	17461	90581669
Vitiligo	131.73	22.18	42	29275	2068	90597062
Rash maculo-papular	119.62	22.18	102	29215	40831	90558299
Drug hypersensitivity	115.99	22.18	9	29308	463600	90135530
Meningitis aseptic	114.91	22.18	52	29265	6721	90592409
Joint swelling	112.42	22.18	15	29302	503285	90095845
Tumour pseudoprogression	111.12	22.18	29	29288	692	90598438
Drug intolerance	111.10	22.18	9	29308	447582	90151548
Hypothalamo-pituitary disorder	109.08	22.18	37	29280	2215	90596915
Adrenocortical insufficiency acute	107.66	22.18	38	29279	2563	90596567
Pain	103.78	22.18	102	29215	996239	89602891
Off label use	102.67	22.18	657	28660	1101595	89497535
Myositis	102.59	22.18	75	29242	24053	90575077
Sepsis	101.81	22.18	197	29120	179617	90419513
Arthropathy	101.15	22.18	4	29313	366238	90232892
Thyroid disorder	98.41	22.18	65	29252	17720	90581410
Myasthenia gravis	95.93	22.18	46	29271	6779	90592351
Immune-mediated pancreatitis	92.37	22.18	22	29295	356	90598774
Pemphigus	92.23	22.18	3	29314	326861	90272269
Immune-mediated adverse reaction	92.18	22.18	26	29291	837	90598293
Intestinal perforation	89.85	22.18	56	29261	13825	90585305
Synovitis	89.72	22.18	4	29313	329748	90269382
Liver disorder	87.95	22.18	148	29169	121121	90478009
Immune-mediated cholangitis	87.41	22.18	20	29297	269	90598861
Autoimmune thyroiditis	86.74	22.18	41	29276	5852	90593278
Encephalitis	85.17	22.18	50	29267	11084	90588046
Non-small cell lung cancer	85.14	22.18	37	29280	4344	90594786
Wound	84.71	22.18	3	29314	302977	90296153
Nasopharyngitis	84.34	22.18	15	29302	407089	90192041
Immune-mediated arthritis	82.20	22.18	19	29298	268	90598862
Swelling	81.45	22.18	18	29299	419040	90180090
Hyponatraemia	80.12	22.18	150	29167	133388	90465742
Blood corticotrophin decreased	79.68	22.18	21	29296	521	90598609
Haemophagocytic lymphohistiocytosis	79.53	22.18	54	29263	15405	90583725
Pleural effusion	78.98	22.18	135	29182	111856	90487274
Abdominal discomfort	78.88	22.18	28	29289	477300	90121830
Drug ineffective	78.24	22.18	212	29105	1384086	89215044
Autoimmune dermatitis	75.60	22.18	16	29301	146	90598984
Alopecia	75.30	22.18	33	29284	495038	90104092
Vogt-Koyanagi-Harada disease	75.28	22.18	19	29298	395	90598735
Maternal exposure during pregnancy	75.15	22.18	13	29304	360050	90239080
Lipase increased	74.89	22.18	46	29271	11065	90588065
Uveitis	73.48	22.18	52	29265	15851	90583279
Peripheral swelling	72.16	22.18	22	29295	413084	90186046
Immune-mediated hyperthyroidism	72.08	22.18	18	29299	358	90598772
Leukoderma	71.30	22.18	14	29303	84	90599046
Aspartate aminotransferase increased	71.16	22.18	123	29194	102814	90496316
Treatment failure	70.39	22.18	8	29309	303920	90295210
Autoimmune nephritis	70.01	22.18	18	29299	404	90598726
Product dose omission issue	69.28	22.18	7	29310	291680	90307450
Nephritis	68.74	22.18	29	29288	3166	90595964
Serous retinal detachment	67.26	22.18	19	29298	615	90598515
Sinusitis	66.12	22.18	15	29302	343073	90256057
Condition aggravated	65.34	22.18	58	29259	595487	90003643
Enteritis	65.19	22.18	41	29276	10280	90588850
Acute kidney injury	64.65	22.18	239	29078	320148	90278982
Dehydration	63.12	22.18	171	29146	194276	90404854
Exposure via body fluid	63.04	22.18	18	29299	606	90598524
Mobility decreased	62.28	22.18	5	29312	250729	90348401
Psoriatic arthropathy	61.34	22.18	3	29314	228332	90370798
Impaired healing	60.08	22.18	4	29313	234195	90364935
Amylase increased	60.07	22.18	34	29283	7038	90592092
Glucocorticoid deficiency	59.95	22.18	17	29300	558	90598572
Adrenalitis	59.92	22.18	11	29306	43	90599087
Guillain-Barre syndrome	58.56	22.18	29	29288	4583	90594547
Exposure during pregnancy	58.53	22.18	5	29312	238405	90360725
Duodenitis	57.08	22.18	28	29289	4335	90594795
Asthma	57.01	22.18	6	29311	242154	90356976
Hypersensitivity	56.51	22.18	39	29278	454638	90144492
Immune-mediated gastritis	56.01	22.18	13	29304	187	90598943
Wheezing	55.79	22.18	6	29311	238074	90361056
Autoimmune arthritis	55.20	22.18	11	29306	72	90599058
Discomfort	54.88	22.18	11	29306	274324	90324806
Rash	54.88	22.18	442	28875	795658	89803472
Thyrotoxic crisis	54.84	22.18	19	29298	1212	90597918
Decreased appetite	54.77	22.18	254	29063	376286	90222844
Blister	53.64	22.18	9	29308	254989	90344141
Musculoskeletal stiffness	53.20	22.18	15	29302	296517	90302613
Iridocyclitis	52.44	22.18	25	29292	3636	90595494
Tubulointerstitial nephritis	52.29	22.18	52	29265	25291	90573839
Immune-mediated myositis	52.17	22.18	22	29295	2399	90596731
Encephalitis autoimmune	52.15	22.18	21	29296	2037	90597093
Drug interaction	51.46	22.18	13	29304	276440	90322690
Alanine aminotransferase increased	50.99	22.18	116	29201	118222	90480908
Diabetes mellitus	50.80	22.18	82	29235	64793	90534337
Weight increased	50.41	22.18	37	29280	417890	90181240
Cholangitis	49.08	22.18	30	29287	7152	90591978
Pericarditis	47.84	22.18	14	29303	270137	90328993
Autoimmune haemolytic anaemia	47.57	22.18	27	29290	5618	90593512
Myasthenic syndrome	47.32	22.18	13	29304	379	90598751
Osteoarthritis	45.68	22.18	5	29312	195725	90403405
Large intestine perforation	45.43	22.18	32	29285	9680	90589450
Hepatic failure	45.34	22.18	60	29257	39668	90559462
Erythema multiforme	45.23	22.18	35	29282	12211	90586919
Dizziness	44.96	22.18	76	29241	589208	90009922
Hyperglycaemia	44.88	22.18	68	29249	50902	90548228
Interstitial lung disease	44.77	22.18	85	29232	76320	90522810
Cortisol decreased	44.75	22.18	18	29299	1741	90597389
Hepatotoxicity	44.46	22.18	64	29253	45778	90553352
Transaminases increased	43.73	22.18	57	29260	37135	90561995
Skin toxicity	42.99	22.18	27	29290	6752	90592378
Drug eruption	42.78	22.18	55	29262	35352	90563778
Respiratory failure	42.33	22.18	108	29209	118310	90480820
Migraine	41.67	22.18	6	29311	190386	90408744
Prescribed overdose	41.28	22.18	95	29222	97530	90501600
Neurofibrosarcoma	40.47	22.18	10	29307	190	90598940
Radiation necrosis	40.39	22.18	13	29304	660	90598470
Gastritis	40.06	22.18	58	29259	41695	90557435
Adrenal disorder	39.80	22.18	17	29300	1913	90597217
Immune-mediated renal disorder	39.26	22.18	10	29307	216	90598914
Memory impairment	39.25	22.18	8	29309	197236	90401894
Pregnancy on contraceptive	39.10	22.18	15	29302	1280	90597850
Metastases to lung	39.03	22.18	36	29281	15955	90583175
Hypoaesthesia	38.95	22.18	27	29290	314183	90284947
Autoimmune pancreatitis	38.94	22.18	11	29306	356	90598774
Disseminated intravascular coagulation	38.65	22.18	41	29276	21497	90577633
Urticaria	38.59	22.18	27	29290	312707	90286423
Therapeutic product effect incomplete	38.30	22.18	8	29309	193888	90405242
Immune-mediated oesophagitis	38.00	22.18	7	29310	28	90599102
Pain in extremity	37.28	22.18	55	29262	450474	90148656
Cholestasis	37.15	22.18	52	29265	36247	90562883
Anaemia	36.75	22.18	217	29100	352585	90246545
Brain oedema	36.47	22.18	36	29281	17349	90581781
Pemphigoid	35.99	22.18	27	29290	8999	90590131
Blood pressure increased	35.32	22.18	10	29307	197207	90401923
Meningitis	35.22	22.18	26	29291	8455	90590675
Product use issue	35.08	22.18	33	29284	329886	90269244
Embolism	34.81	22.18	27	29290	9454	90589676
Gastrooesophageal reflux disease	34.69	22.18	6	29311	166331	90432799
Overdose	34.44	22.18	5	29312	157704	90441426
Tumour pain	33.64	22.18	15	29302	1872	90597258
Gait inability	33.52	22.18	4	29313	146452	90452678
Fall	33.28	22.18	66	29251	481744	90117386
Lower respiratory tract infection	33.15	22.18	20	29297	250639	90348491
Immune-mediated encephalopathy	32.99	22.18	6	29311	22	90599108
Autoimmune myocarditis	32.87	22.18	9	29308	259	90598871
Feeling abnormal	32.82	22.18	7	29310	167228	90431902
Septic shock	32.43	22.18	79	29238	84081	90515049
Autoimmune hypothyroidism	32.29	22.18	9	29308	277	90598853
Arthralgia	32.28	22.18	136	29181	778386	89820744
Sleep disorder	32.01	22.18	12	29305	198018	90401112
Silent thyroiditis	31.94	22.18	8	29309	161	90598969
Pancreatitis	31.80	22.18	70	29247	69756	90529374
Capillary leak syndrome	31.03	22.18	16	29301	2751	90596379
Drug reaction with eosinophilia and systemic symptoms	30.72	22.18	52	29265	42706	90556424
Multiple organ dysfunction syndrome	30.55	22.18	68	29249	68268	90530862
Pancreatic failure	30.30	22.18	13	29304	1479	90597651
Glomerulonephritis minimal lesion	29.95	22.18	9	29308	363	90598767
Infusion related reaction	29.73	22.18	56	29261	416724	90182406
Muscle spasms	29.45	22.18	23	29294	251860	90347270
Blood thyroid stimulating hormone decreased	29.40	22.18	20	29297	5720	90593410
Systemic inflammatory response syndrome	29.39	22.18	21	29296	6495	90592635
Dermatitis	29.20	22.18	36	29281	22184	90576946
Bursitis	29.15	22.18	4	29313	131650	90467480
Demyelinating polyneuropathy	28.76	22.18	11	29306	931	90598199
Type 2 diabetes mellitus	28.62	22.18	15	29302	203229	90395901
Endocrine disorder	28.55	22.18	11	29306	949	90598181
Meningoradiculitis	28.48	22.18	7	29310	130	90599000
Contusion	28.05	22.18	24	29293	251192	90347938
Rheumatoid arthritis	27.40	22.18	47	29270	362567	90236563
Hypokalaemia	27.39	22.18	99	29218	131017	90468113
Dyspepsia	27.36	22.18	15	29302	198145	90400985
Adverse drug reaction	27.18	22.18	3	29314	116698	90482432
Propionibacterium infection	26.95	22.18	5	29312	21	90599109
Pericardial effusion	26.73	22.18	45	29272	36788	90562342
Chronic gastritis	26.52	22.18	16	29301	3725	90595405
Chorioretinitis	26.41	22.18	10	29307	823	90598307
Adenocarcinoma	26.16	22.18	15	29302	3181	90595949
Tumour haemorrhage	26.09	22.18	13	29304	2081	90597049
Oesophagitis	26.05	22.18	30	29287	17219	90581911
Drug-induced liver injury	25.91	22.18	76	29241	90242	90508888
Neoplasm progression	25.45	22.18	49	29268	44437	90554693
Facial paralysis	25.13	22.18	28	29289	15506	90583624
Immune thrombocytopenia	25.04	22.18	26	29291	13300	90585830
Cholecystitis	24.67	22.18	29	29288	17011	90582119
Hypertension	24.22	22.18	72	29245	457460	90141670
Pulmonary embolism	24.19	22.18	95	29222	130725	90468405
Loss of personal independence in daily activities	24.18	22.18	7	29310	136098	90463032
Hepatic cytolysis	24.09	22.18	39	29278	30877	90568253
Optic neuritis	24.03	22.18	22	29295	9656	90589474
Aplasia pure red cell	24.03	22.18	17	29300	5177	90593953
Immune-mediated endocrinopathy	23.67	22.18	6	29311	127	90599003
Depression	23.60	22.18	38	29279	300563	90298567
Metastases to liver	23.35	22.18	37	29280	28770	90570360
Immune-mediated cystitis	23.30	22.18	5	29312	49	90599081
Sciatica	22.64	22.18	3	29314	101379	90497751
Pituitary enlargement	22.61	22.18	5	29312	57	90599073
Inflammation	22.58	22.18	15	29302	178577	90420553
Hypercalcaemia	22.45	22.18	40	29277	34200	90564930
Primary hypothyroidism	22.35	22.18	6	29311	160	90598970

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	2764.29	17.05	1688	50383	106712	42462552
Immune-mediated enterocolitis	1856.30	17.05	548	51523	5129	42564135
Hypophysitis	1752.38	17.05	457	51614	2554	42566710
Colitis	1687.79	17.05	914	51157	45658	42523606
Adrenal insufficiency	1010.16	17.05	483	51588	18441	42550823
Hypopituitarism	810.53	17.05	246	51825	2545	42566719
Immune-mediated hepatitis	769.48	17.05	254	51817	3520	42565744
Immune-mediated lung disease	653.33	17.05	220	51851	3253	42566011
Immune-mediated hepatic disorder	647.05	17.05	202	51869	2312	42566952
Immune-mediated dermatitis	617.34	17.05	167	51904	1094	42568170
Pneumonitis	613.45	17.05	464	51607	41254	42528010
Hypothyroidism	604.82	17.05	415	51656	31669	42537595
Hyperthyroidism	533.70	17.05	287	51784	14054	42555210
Autoimmune colitis	520.78	17.05	143	51928	998	42568266
Thyroiditis	515.38	17.05	181	51890	3055	42566209
Immune-mediated myocarditis	497.44	17.05	159	51912	1975	42567289
Autoimmune hepatitis	470.62	17.05	197	51874	5448	42563816
Intentional product use issue	469.93	17.05	506	51565	71327	42497937
Type 1 diabetes mellitus	429.16	17.05	183	51888	5304	42563960
Secondary adrenocortical insufficiency	410.76	17.05	137	51934	1962	42567302
Fulminant type 1 diabetes mellitus	407.01	17.05	123	51948	1251	42568013
Myocarditis	387.84	17.05	258	51813	18680	42550584
Adrenocorticotropic hormone deficiency	381.71	17.05	117	51954	1253	42568011
Death	380.45	17.05	1348	50723	469837	42099427
Immune-mediated hypothyroidism	372.88	17.05	113	51958	1161	42568103
Hepatitis	358.24	17.05	284	51787	27016	42542248
Immune-mediated hypophysitis	356.06	17.05	86	51985	329	42568935
Prescribed overdose	352.13	17.05	211	51860	12716	42556548
Lymphocytic hypophysitis	336.37	17.05	81	51990	305	42568959
Diarrhoea	330.98	17.05	1270	50801	459579	42109685
Immune-mediated adrenal insuficiency	319.38	17.05	89	51982	660	42568604
Enterocolitis	309.83	17.05	177	51894	9752	42559512
Diabetic ketoacidosis	274.95	17.05	224	51847	22143	42547121
Liver disorder	267.30	17.05	284	51787	39360	42529904
Myositis	260.50	17.05	184	51887	14682	42554582
Vitiligo	246.67	17.05	82	51989	1161	42568103
Hepatic function abnormal	242.77	17.05	307	51764	51260	42518004
Drug interaction	232.78	17.05	27	52044	266972	42302292
Immune-mediated thyroiditis	216.00	17.05	60	52011	439	42568825
Pyrexia	206.98	17.05	989	51082	393053	42176211
Hypothalamo-pituitary disorder	204.15	17.05	69	52002	1031	42568233
Drug ineffective	201.97	17.05	287	51784	629910	41939354
Non-small cell lung cancer	200.37	17.05	105	51966	4869	42564395
Rash	198.36	17.05	764	51307	276190	42293074
Cytokine release syndrome	193.74	17.05	255	51816	44272	42524992
Interstitial lung disease	181.84	17.05	336	51735	78126	42491138
Immune-mediated myositis	181.68	17.05	90	51981	3703	42565561
Metastases to central nervous system	181.01	17.05	128	51943	10227	42559037
Immune-mediated uveitis	180.42	17.05	40	52031	93	42569171
Immune-mediated nephritis	168.14	17.05	54	52017	681	42568583
Uveitis	160.80	17.05	114	51957	9144	42560120
Immune-mediated encephalitis	145.82	17.05	47	52024	600	42568664
Toxicity to various agents	142.60	17.05	51	52020	229085	42340179
Immune-mediated hyperthyroidism	138.84	17.05	36	52035	195	42569069
Immune-mediated adverse reaction	137.42	17.05	50	52021	938	42568326
Adverse event	136.16	17.05	156	51915	23484	42545780
Product dose omission issue	126.26	17.05	19	52052	154346	42414918
Lipase increased	125.98	17.05	104	51967	10462	42558802
Thyroid disorder	124.77	17.05	71	52000	3879	42565385
Autoimmune thyroiditis	124.46	17.05	53	52018	1529	42567735
Nephritis	122.09	17.05	69	52002	3720	42565544
Blood thyroid stimulating hormone decreased	113.87	17.05	56	52015	2267	42566997
Pulmonary toxicity	111.23	17.05	89	51982	8566	42560698
Encephalitis	110.98	17.05	91	51980	9067	42560197
Immune-mediated pancreatitis	108.39	17.05	32	52039	298	42568966
Myasthenia gravis	105.85	17.05	114	51957	16023	42553241
Immune-mediated cholangitis	101.40	17.05	34	52037	495	42568769
Decreased appetite	99.55	17.05	483	51588	192654	42376610
Pemphigoid	99.01	17.05	94	51977	11373	42557891
Tumour pseudoprogression	98.89	17.05	40	52031	1010	42568254
Leukoderma	98.77	17.05	23	52048	72	42569192
Haemophagocytic lymphohistiocytosis	97.83	17.05	116	51955	18106	42551158
Completed suicide	97.18	17.05	5	52066	96460	42472804
Overdose	95.80	17.05	9	52062	105255	42464009
Immune-mediated renal disorder	93.04	17.05	31	52040	442	42568822
Autoimmune nephritis	91.65	17.05	28	52043	296	42568968
Cortisol decreased	88.42	17.05	40	52031	1338	42567926
Prescribed underdose	88.23	17.05	84	51987	10198	42559066
Immune-mediated arthritis	87.99	17.05	27	52044	290	42568974
Adrenocortical insufficiency acute	87.05	17.05	46	52025	2169	42567095
Rash maculo-papular	84.77	17.05	159	51912	37344	42531920
Meningitis aseptic	84.39	17.05	58	52013	4424	42564840
Adrenal disorder	83.78	17.05	37	52034	1168	42568096
Radiation pneumonitis	82.77	17.05	49	52022	2884	42566380
Intestinal perforation	82.41	17.05	83	51988	10791	42558473
Guillain-Barre syndrome	81.43	17.05	69	52002	7194	42562070
Skin disorder	79.84	17.05	101	51970	16843	42552421
Large intestine perforation	78.22	17.05	76	51995	9460	42559804
Immune-mediated endocrinopathy	77.38	17.05	18	52053	56	42569208
Erythema multiforme	75.32	17.05	76	51995	9901	42559363
Dermatitis	74.58	17.05	82	51989	11793	42557471
Condition aggravated	74.21	17.05	128	51943	260626	42308638
Facial paralysis	72.48	17.05	83	51988	12480	42556784
Tubulointerstitial nephritis	71.60	17.05	134	51937	31414	42537850
Hyperglycaemia	69.36	17.05	165	51906	45694	42523570
Drug hypersensitivity	69.17	17.05	18	52053	99371	42469893
Autoimmune pancreatitis	68.86	17.05	24	52047	395	42568869
Autoimmune disorder	68.74	17.05	41	52030	2446	42566818
Blood corticotrophin decreased	67.89	17.05	22	52049	286	42568978
Endocrine disorder	67.59	17.05	23	52048	351	42568913
Amylase increased	67.51	17.05	60	52011	6669	42562595
Blood pressure increased	66.25	17.05	21	52050	101907	42467357
Hepatotoxicity	64.89	17.05	113	51958	25054	42544210
Hypercalcaemia	64.36	17.05	94	51977	17964	42551300
Hyponatraemia	64.35	17.05	270	51801	101192	42468072
Autoimmune haemolytic anaemia	63.83	17.05	54	52017	5617	42563647
Immune-mediated cystitis	63.28	17.05	16	52055	77	42569187
Agitation	62.72	17.05	4	52067	64310	42504954
Fall	62.35	17.05	120	51951	234400	42334864
Anxiety	61.69	17.05	34	52037	118526	42450738
Haemoglobin decreased	60.67	17.05	44	52027	132427	42436837
Immune-mediated gastritis	59.50	17.05	16	52055	102	42569162
Somnolence	59.42	17.05	51	52020	141054	42428210
Radiation necrosis	58.63	17.05	19	52052	247	42569017
Feeling abnormal	58.39	17.05	8	52063	69778	42499486
Enteritis	58.29	17.05	69	52002	10747	42558517
Pain	56.19	17.05	136	51935	244712	42324552
Dizziness	55.21	17.05	141	51930	249113	42320151
Inappropriate schedule of product administration	55.20	17.05	24	52047	95878	42473386
Intracranial tumour haemorrhage	54.53	17.05	20	52051	384	42568880
Aspartate aminotransferase increased	54.21	17.05	212	51859	76951	42492313
Myasthenic syndrome	53.21	17.05	24	52047	797	42568467
Serous retinal detachment	53.07	17.05	25	52046	919	42568345
Vogt-Koyanagi-Harada disease	51.16	17.05	16	52055	184	42569080
Pain in extremity	50.46	17.05	66	52005	150538	42418726
Silent thyroiditis	47.93	17.05	13	52058	86	42569178
Off label use	46.89	17.05	1063	51008	637272	41931992
Encephalitis autoimmune	46.87	17.05	26	52045	1351	42567913
Alanine aminotransferase increased	46.80	17.05	223	51848	88183	42481081
Enterocolitis haemorrhagic	46.72	17.05	24	52047	1067	42568197
Joint swelling	46.03	17.05	13	52058	68009	42501255
Iridocyclitis	44.93	17.05	30	52041	2181	42567083
Suicide attempt	44.55	17.05	3	52068	46097	42523167
Sialoadenitis	44.03	17.05	21	52050	794	42568470
Immune thrombocytopenia	43.81	17.05	61	52010	11155	42558109
Bradycardia	43.76	17.05	25	52046	85459	42483805
Autoimmune neuropathy	43.16	17.05	11	52060	55	42569209
Tri-iodothyronine free decreased	42.83	17.05	11	52060	57	42569207
Coma	42.82	17.05	7	52064	53547	42515717
Hallucination	42.80	17.05	9	52062	57498	42511766
Peripheral swelling	42.61	17.05	29	52042	90241	42479023
Immune-mediated encephalopathy	42.06	17.05	11	52060	62	42569202
Pituitary enlargement	41.85	17.05	9	52062	17	42569247
Therapeutic product effect incomplete	40.42	17.05	18	52053	70921	42498343
Drug eruption	40.40	17.05	88	51983	22987	42546277
Depression	40.25	17.05	46	52025	111317	42457947
Asthma	40.19	17.05	13	52058	62301	42506963
Autoimmune dermatitis	40.10	17.05	10	52061	45	42569219
Incorrect dose administered	40.03	17.05	8	52063	52966	42516298
Cardiac failure congestive	39.74	17.05	28	52043	85574	42483690
Weight increased	39.69	17.05	44	52027	107939	42461325
Tremor	39.62	17.05	36	52035	96893	42472371
Autoimmune arthritis	39.61	17.05	12	52059	123	42569141
Treatment failure	38.77	17.05	14	52057	62610	42506654
Hypertension	38.22	17.05	93	51978	167111	42402153
Meningitis	38.02	17.05	41	52030	5768	42563496
Wheezing	37.95	17.05	10	52061	54771	42514493
Aggression	37.08	17.05	5	52066	44158	42525106
General physical health deterioration	36.90	17.05	313	51758	150933	42418331
Disseminated intravascular coagulation	36.17	17.05	88	51983	24706	42544558
Myocardial infarction	36.01	17.05	60	52011	123949	42445315
Blood glucose increased	35.69	17.05	23	52048	73676	42495588
Glucocorticoid deficiency	35.45	17.05	16	52055	532	42568732
Immune-mediated neuropathy	35.32	17.05	10	52061	79	42569185
Chest discomfort	34.92	17.05	17	52054	63599	42505665
Loss of personal independence in daily activities	34.68	17.05	9	52062	49807	42519457
Polymyalgia rheumatica	34.43	17.05	26	52045	2297	42566967
Drug-induced liver injury	34.40	17.05	114	51957	38159	42531105
White blood cell count decreased	34.34	17.05	51	52020	110345	42458919
Pruritus	34.30	17.05	367	51704	188404	42380860
Skin toxicity	34.01	17.05	41	52030	6508	42562756
Giant cell arteritis	33.76	17.05	20	52051	1178	42568086
Orbital myositis	33.73	17.05	11	52060	146	42569118
Pancreatic enzymes increased	33.71	17.05	18	52053	867	42568397
Cytomegalovirus enterocolitis	33.61	17.05	21	52050	1362	42567902
Prostate cancer	33.19	17.05	7	52064	44636	42524628
Chest pain	33.16	17.05	76	51995	139454	42429810
Wrong technique in product usage process	33.14	17.05	6	52065	42629	42526635
Duodenitis	32.54	17.05	37	52034	5519	42563745
Pleural effusion	32.10	17.05	216	51855	96950	42472314
Hyperhidrosis	32.04	17.05	38	52033	90474	42478790
Melanoma recurrent	32.02	17.05	11	52060	173	42569091
Insomnia	31.82	17.05	60	52011	118193	42451071
Arthritis	31.52	17.05	118	51953	41947	42527317
Lichenoid keratosis	31.49	17.05	31	52040	3919	42565345
Autoimmune lung disease	30.96	17.05	9	52062	79	42569185
Angioedema	30.89	17.05	7	52064	42470	42526794
Epistaxis	30.83	17.05	22	52049	66804	42502460
Muscle spasms	30.59	17.05	36	52035	86008	42483256
Pancreatic toxicity	30.16	17.05	8	52063	48	42569216
Intestinal intraepithelial lymphocytes increased	30.15	17.05	11	52060	208	42569056
Coronary artery disease	30.03	17.05	14	52057	53706	42515558
Nasopharyngitis	30.01	17.05	35	52036	83961	42485303
Thyroxine free decreased	29.85	17.05	12	52059	298	42568966
Cholangitis sclerosing	29.78	17.05	22	52049	1880	42567384
Pericardial effusion	29.78	17.05	91	51980	29184	42540080
Abdominal discomfort	29.52	17.05	29	52042	75226	42494038
Musculoskeletal stiffness	29.40	17.05	17	52054	57748	42511516
Prerenal failure	29.11	17.05	24	52047	2409	42566855
Dehydration	28.78	17.05	282	51789	141485	42427779
Heart rate decreased	28.70	17.05	5	52066	36527	42532737
Tumour associated fever	28.57	17.05	14	52057	562	42568702
Immune-mediated cytopenia	27.92	17.05	10	52061	179	42569085
Hepatic cytolysis	27.83	17.05	84	51987	26760	42542504
Thrombophlebitis migrans	27.80	17.05	12	52059	358	42568906
Autoimmune myocarditis	27.71	17.05	11	52060	264	42569000
Iris adhesions	27.56	17.05	11	52060	268	42568996
Adrenalitis	27.46	17.05	7	52064	35	42569229
Hypertransaminasaemia	27.20	17.05	44	52027	9183	42560081
Drug intolerance	27.17	17.05	35	52036	80389	42488875
Cryptitis	27.11	17.05	11	52060	280	42568984
Chronic gastritis	26.97	17.05	22	52049	2175	42567089
Haematocrit decreased	26.94	17.05	5	52066	34903	42534361
Nephrolithiasis	26.92	17.05	6	52065	36824	42532440
Swelling	26.75	17.05	17	52054	54868	42514396
Sedation	26.69	17.05	3	52068	30472	42538792
Heart rate increased	26.64	17.05	16	52055	53239	42516025
Polymyositis	26.63	17.05	20	52051	1753	42567511
International normalised ratio increased	26.24	17.05	13	52058	48155	42521109
Full blood count abnormal	26.02	17.05	3	52068	29873	42539391
Cortisol increased	25.92	17.05	10	52061	222	42569042
Metastases to skin	25.79	17.05	13	52058	555	42568709
Palpitations	25.78	17.05	15	52056	50782	42518482
Metastases to lymph nodes	25.51	17.05	34	52037	5964	42563300
Microvillous inclusion disease	25.47	17.05	10	52061	233	42569031
Metastases to lung	25.26	17.05	48	52023	11376	42557888
Pleurocutaneous fistula	25.22	17.05	7	52064	51	42569213
Lichen planus	25.17	17.05	17	52054	1260	42568004
Polyarthritis	24.96	17.05	31	52040	5073	42564191
Meningoradiculitis	24.87	17.05	7	52064	54	42569210
White blood cell count increased	24.81	17.05	12	52059	45075	42524189
Sarcoid-like reaction	24.76	17.05	8	52063	103	42569161
Electrocardiogram QT prolonged	24.56	17.05	14	52057	47931	42521333
Accidental overdose	24.28	17.05	3	52068	28327	42540937
Achromotrichia acquired	24.06	17.05	6	52065	27	42569237
Tachycardia	24.06	17.05	55	52016	101032	42468232
Adverse drug reaction	23.80	17.05	8	52063	37426	42531838
Rheumatic disorder	23.75	17.05	13	52058	658	42568606
Thyroid function test abnormal	23.30	17.05	13	52058	683	42568581
Optic neuritis	23.27	17.05	27	52044	4115	42565149
Unresponsive to stimuli	23.19	17.05	5	52066	31398	42537866
Haemorrhage	22.99	17.05	24	52047	60539	42508725
Primary adrenal insufficiency	22.93	17.05	10	52061	306	42568958
Drug dependence	22.82	17.05	4	52067	29090	42540174
Metastases to meninges	22.74	17.05	19	52052	1942	42567322
Tumour haemorrhage	22.63	17.05	25	52046	3613	42565651
Lower respiratory tract infection	22.63	17.05	11	52060	41195	42528069
Gait disturbance	21.98	17.05	55	52016	97945	42471319
Transient ischaemic attack	21.82	17.05	7	52064	33732	42535532
Probiotic therapy	21.75	17.05	8	52063	155	42569109
Bile duct stenosis	21.61	17.05	16	52055	1372	42567892
Blood corticotrophin increased	21.60	17.05	8	52063	158	42569106
Gastrointestinal perforation	21.54	17.05	27	52044	4459	42564805
Loss of consciousness	21.37	17.05	51	52020	92303	42476961
Cholangitis	21.21	17.05	43	52028	10684	42558580
Thyrotoxic crisis	21.12	17.05	13	52058	821	42568443
Pneumonia bacterial	21.10	17.05	54	52017	15638	42553626
Influenza	21.06	17.05	27	52044	62148	42507116
Disease progression	21.05	17.05	97	51974	143559	42425705
Blood thyroid stimulating hormone increased	21.00	17.05	29	52042	5263	42564001
Blood urea increased	20.86	17.05	7	52064	32786	42536478
Red blood cell count decreased	20.78	17.05	7	52064	32708	42536556
Sleep disorder	20.69	17.05	17	52054	48078	42521186
Cerebrovascular accident	20.67	17.05	56	52015	97104	42472160
Neutropenia	20.49	17.05	151	51920	199280	42369984
Autoimmune hypothyroidism	20.35	17.05	8	52063	187	42569077
Metabolic acidosis	20.31	17.05	20	52051	51838	42517426
Tumour pain	20.20	17.05	15	52056	1292	42567972
Oxygen saturation decreased	19.99	17.05	30	52041	64657	42504607
Muscular weakness	19.91	17.05	172	51899	83326	42485938
Spermatogenesis abnormal	19.76	17.05	6	52065	62	42569202
Fluid retention	19.68	17.05	7	52064	31612	42537652
Apoptosis	19.65	17.05	11	52060	582	42568682
Metastatic malignant melanoma	19.62	17.05	19	52052	2354	42566910
Diabetes mellitus	19.49	17.05	133	51938	59954	42509310
Arthropathy	19.39	17.05	6	52065	29591	42539673
Nasal congestion	19.29	17.05	6	52065	29495	42539769
Gastrooesophageal reflux disease	19.26	17.05	16	52055	45007	42524257
Pulmonary sepsis	19.24	17.05	22	52049	3302	42565962
Blood corticotrophin abnormal	19.14	17.05	5	52066	28	42569236
Contusion	19.13	17.05	14	52057	41971	42527293
Thrombosis	19.09	17.05	34	52037	68477	42500787
Pulmonary sarcoidosis	19.07	17.05	12	52059	788	42568476
Psychotic disorder	19.00	17.05	6	52065	29202	42540062
Serous retinopathy	18.87	17.05	8	52063	228	42569036
Parvovirus infection	18.72	17.05	10	52061	482	42568782
Hepatic failure	18.64	17.05	94	51977	38006	42531258
Gastritis	18.62	17.05	68	52003	23879	42545385
Mobility decreased	18.53	17.05	10	52061	35296	42533968
Erectile dysfunction	18.33	17.05	4	52067	24909	42544355
Myelitis	18.15	17.05	13	52058	1059	42568205
Confusional state	18.13	17.05	125	51946	167472	42401792
Transient acantholytic dermatosis	17.98	17.05	8	52063	257	42569007
Cancer pain	17.98	17.05	22	52049	3545	42565719
Balance disorder	17.95	17.05	19	52052	47626	42521638
Disturbance in attention	17.94	17.05	7	52064	29859	42539405
Cardiac disorder	17.90	17.05	20	52051	48912	42520352
Autoimmune thyroid disorder	17.84	17.05	4	52067	10	42569254
Product prescribing error	17.64	17.05	5	52066	26107	42543157
Acute myeloid leukaemia	17.58	17.05	3	52068	22253	42547011
Physical deconditioning	17.57	17.05	18	52053	2387	42566877
Therapeutic response decreased	17.31	17.05	12	52059	37000	42532264
Product use issue	17.27	17.05	43	52028	76708	42492556
Opsoclonus myoclonus	17.26	17.05	6	52065	98	42569166
Primary hypothyroidism	17.26	17.05	6	52065	98	42569166

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	4954.93	17.36	2405	73765	172162	110340967
Immune-mediated enterocolitis	3090.82	17.36	819	75351	9366	110503763
Hypophysitis	2945.05	17.36	695	75475	4720	110508409
Colitis	2479.27	17.36	1269	74901	101054	110412075
Adrenal insufficiency	1521.12	17.36	689	75481	41701	110471428
Immune-mediated hepatitis	1452.64	17.36	414	75756	6297	110506832
Hypopituitarism	1293.08	17.36	345	75825	4045	110509084
Immune-mediated hepatic disorder	1241.31	17.36	335	75835	4115	110509014
Immune-mediated lung disease	1079.92	17.36	312	75858	4991	110508138
Hypothyroidism	1067.07	17.36	650	75520	72249	110440880
Pneumonitis	1032.91	17.36	648	75522	75883	110437246
Immune-mediated dermatitis	1003.24	17.36	247	75923	2043	110511086
Hyperthyroidism	956.57	17.36	446	75724	28815	110484314
Death	898.17	17.36	1670	74500	697199	109815930
Thyroiditis	867.57	17.36	277	75893	6296	110506833
Autoimmune colitis	858.95	17.36	212	75958	1773	110511356
Type 1 diabetes mellitus	795.99	17.36	281	75889	8766	110504363
Immune-mediated myocarditis	766.84	17.36	218	75952	3280	110509849
Fulminant type 1 diabetes mellitus	740.13	17.36	195	75975	2168	110510961
Autoimmune hepatitis	711.76	17.36	296	75874	14508	110498621
Myocarditis	706.81	17.36	366	75804	29689	110483440
Immune-mediated hypophysitis	661.22	17.36	150	76020	831	110512298
Secondary adrenocortical insufficiency	648.06	17.36	202	75968	4232	110508897
Immune-mediated hypothyroidism	642.98	17.36	182	75988	2693	110510436
Adrenocorticotropic hormone deficiency	597.87	17.36	162	76008	2020	110511109
Lymphocytic hypophysitis	527.27	17.36	117	76053	576	110512553
Enterocolitis	516.39	17.36	255	75915	18694	110494435
Diabetic ketoacidosis	514.64	17.36	335	75835	41723	110471406
Hepatic function abnormal	490.20	17.36	441	75729	88854	110424275
Immune-mediated adrenal insuficiency	482.30	17.36	131	76039	1649	110511480
Diarrhoea	472.38	17.36	1784	74386	1137721	109375408
Immune-mediated thyroiditis	463.84	17.36	115	76055	981	110512148
Cytokine release syndrome	437.63	17.36	373	75797	69933	110443196
Hepatitis	402.75	17.36	397	75773	89657	110423472
Pyrexia	393.70	17.36	1433	74737	896832	109616297
Intentional product use issue	384.47	17.36	645	75525	247261	110265868
Myositis	371.24	17.36	244	75926	30872	110482257
Vitiligo	364.85	17.36	119	76051	2898	110510231
Immune-mediated uveitis	347.73	17.36	71	76099	213	110512916
Immune-mediated nephritis	340.02	17.36	92	76078	1140	110511989
Immune-mediated encephalitis	324.38	17.36	88	76082	1102	110512027
Non-small cell lung cancer	309.93	17.36	137	76033	7798	110505331
Interstitial lung disease	301.13	17.36	423	75747	138911	110374218
Liver disorder	288.54	17.36	419	75751	141824	110371305
Hypothalamo-pituitary disorder	287.39	17.36	98	76072	2748	110510381
Metastases to central nervous system	277.23	17.36	181	75989	22636	110490493
Immune-mediated myositis	242.23	17.36	107	76063	6079	110507050
Uveitis	224.89	17.36	156	76014	21554	110491575
Drug hypersensitivity	222.63	17.36	26	76144	454064	110059065
Joint swelling	220.52	17.36	24	76146	442821	110070308
Myasthenia gravis	214.50	17.36	151	76019	21360	110491769
Drug interaction	212.63	17.36	43	76127	500140	110012989
Lipase increased	212.01	17.36	142	76028	18530	110494599
Pain	209.31	17.36	210	75960	954745	109558384
Tumour pseudoprogression	208.68	17.36	67	76103	1549	110511580
Immune-mediated hyperthyroidism	207.11	17.36	54	76116	574	110512555
Immune-mediated adverse reaction	205.34	17.36	67	76103	1633	110511496
Rash maculo-papular	202.98	17.36	253	75917	73969	110439160
Drug ineffective	199.71	17.36	474	75696	1520066	108993063
Immune-mediated pancreatitis	194.82	17.36	53	76117	671	110512458
Meningitis aseptic	194.78	17.36	107	76063	9763	110503366
Encephalitis	189.60	17.36	133	76037	18706	110494423
Immune-mediated cholangitis	188.83	17.36	54	76116	830	110512299
Autoimmune thyroiditis	185.48	17.36	90	76080	6344	110506785
Haemophagocytic lymphohistiocytosis	181.25	17.36	160	76010	31399	110481730
Leukoderma	181.14	17.36	39	76131	162	110512967
Adrenocortical insufficiency acute	177.73	17.36	78	76092	4362	110508767
Drug intolerance	174.70	17.36	34	76136	406478	110106651
Toxicity to various agents	169.01	17.36	60	76110	480495	110032634
Immune-mediated arthritis	165.96	17.36	46	76124	627	110512502
Nephritis	165.56	17.36	82	76088	6044	110507085
Rash	161.29	17.36	1041	75129	819923	109693206
Synovitis	158.94	17.36	7	76163	274085	110239044
Arthropathy	158.41	17.36	10	76160	287512	110225617
Decreased appetite	158.33	17.36	698	75472	475148	110037981
Prescribed overdose	157.53	17.36	244	75926	87337	110425792
Peripheral swelling	157.23	17.36	42	76128	403992	110109137
Systemic lupus erythematosus	156.25	17.36	4	76166	254334	110258795
Swelling	155.90	17.36	27	76143	351014	110162115
Therapeutic product effect decreased	153.38	17.36	3	76167	244313	110268816
Immune-mediated renal disorder	152.27	17.36	44	76126	703	110512426
Nasopharyngitis	147.87	17.36	44	76126	394317	110118812
Hyponatraemia	147.85	17.36	405	75765	217248	110295881
Condition aggravated	146.00	17.36	175	75995	734661	109778468
Completed suicide	144.58	17.36	5	76165	242376	110270753
Intestinal perforation	144.50	17.36	118	76052	20826	110492303
Pemphigoid	142.24	17.36	114	76056	19593	110493536
Pulmonary toxicity	141.78	17.36	109	76061	17637	110495492
Guillain-Barre syndrome	139.80	17.36	89	76081	10655	110502474
Tubulointerstitial nephritis	138.84	17.36	179	75991	54105	110459024
Abdominal discomfort	138.75	17.36	49	76121	393809	110119320
Aspartate aminotransferase increased	138.17	17.36	326	75844	159610	110353519
Maternal exposure during pregnancy	137.08	17.36	10	76160	254873	110258256
Off label use	135.94	17.36	1602	74568	1498583	109014546
Blood corticotrophin decreased	133.80	17.36	41	76129	809	110512320
Hyperglycaemia	133.78	17.36	223	75947	84867	110428262
Wound	132.66	17.36	7	76163	234430	110278699
Autoimmune nephritis	131.76	17.36	40	76130	764	110512365
Pleural effusion	129.05	17.36	339	75831	177370	110335759
Large intestine perforation	128.19	17.36	100	76070	16529	110496600
Blood thyroid stimulating hormone decreased	127.94	17.36	73	76097	7166	110505963
Alopecia	127.41	17.36	46	76124	364707	110148422
Erythema multiforme	127.25	17.36	110	76060	20987	110492142
Radiation pneumonitis	126.40	17.36	62	76108	4474	110508655
Overdose	126.22	17.36	9	76161	233785	110279344
Treatment failure	126.02	17.36	20	76150	277214	110235915
Weight increased	125.89	17.36	66	76104	419578	110093551
Amylase increased	125.08	17.36	88	76082	12431	110500698
Product dose omission issue	124.13	17.36	34	76136	321748	110191381
Cortisol decreased	123.91	17.36	53	76117	2783	110510346
Thyroid disorder	122.13	17.36	98	76072	16871	110496258
Enteritis	121.91	17.36	103	76067	19053	110494076
Wheezing	121.61	17.36	16	76154	255214	110257915
Adrenal disorder	118.11	17.36	49	76121	2383	110510746
Mobility decreased	117.76	17.36	13	76157	237409	110275720
Pemphigus	116.59	17.36	8	76162	214562	110298567
Alanine aminotransferase increased	114.03	17.36	331	75839	183442	110329687
Autoimmune haemolytic anaemia	111.95	17.36	77	76093	10490	110502639
Asthma	111.65	17.36	19	76151	250272	110262857
Metastatic malignant melanoma	111.44	17.36	52	76118	3357	110509772
Vogt-Koyanagi-Harada disease	111.11	17.36	33	76137	583	110512546
Musculoskeletal stiffness	110.90	17.36	28	76142	279794	110233335
Serous retinal detachment	110.22	17.36	42	76128	1630	110511499
Sinusitis	109.56	17.36	34	76136	296654	110216475
Dizziness	105.07	17.36	201	75969	697992	109815137
Autoimmune pancreatitis	104.85	17.36	34	76136	812	110512317
Blood pressure increased	104.05	17.36	25	76145	258348	110254781
Impaired healing	102.19	17.36	9	76161	196708	110316421
Hepatotoxicity	102.13	17.36	168	76002	63232	110449897
Immune-mediated gastritis	101.58	17.36	27	76143	311	110512818
Facial paralysis	101.25	17.36	103	76067	24111	110489018
Dehydration	100.49	17.36	420	75750	279091	110234038
Hypersensitivity	100.05	17.36	79	76091	403919	110109210
Skin disorder	96.66	17.36	133	76037	42780	110470349
Pain in extremity	95.57	17.36	117	76053	487001	110026128
Exposure during pregnancy	94.71	17.36	5	76165	167419	110345710
Blister	93.54	17.36	21	76149	227355	110285774
Osteoarthritis	93.14	17.36	9	76161	182614	110330515
Radiation necrosis	92.50	17.36	31	76139	823	110512306
Product use issue	92.01	17.36	50	76120	311645	110201484
Folliculitis	91.81	17.36	6	76164	167647	110345482
Disseminated intravascular coagulation	91.56	17.36	127	76043	41159	110471970
Immune-mediated endocrinopathy	91.28	17.36	21	76149	125	110513004
Myasthenic syndrome	91.17	17.36	34	76136	1242	110511887
Dermatitis	91.07	17.36	104	76066	27733	110485396
Sepsis	90.28	17.36	455	75715	326891	110186238
Discomfort	90.00	17.36	19	76151	214688	110298441
Lower respiratory tract infection	89.49	17.36	28	76142	243078	110270051
Therapeutic product effect incomplete	89.43	17.36	22	76148	223783	110289346
Acute kidney injury	89.05	17.36	744	75426	634686	109878443
Iridocyclitis	88.82	17.36	52	76118	5356	110507773
Encephalitis autoimmune	88.79	17.36	45	76125	3483	110509646
Glucocorticoid deficiency	86.31	17.36	32	76138	1150	110511979
Autoimmune dermatitis	86.23	17.36	22	76148	213	110512916
Migraine	86.13	17.36	9	76161	171643	110341486
Duodenitis	85.79	17.36	62	76108	9134	110503995
Hypercalcaemia	85.29	17.36	131	76039	46526	110466603
Immune-mediated cystitis	85.03	17.36	20	76150	133	110512996
Feeling abnormal	84.48	17.36	12	76158	180699	110332430
Fall	83.71	17.36	182	75988	603300	109909829
Psoriatic arthropathy	83.32	17.36	17	76153	196744	110316385
Autoimmune arthritis	81.79	17.36	22	76148	266	110512863
Drug eruption	80.84	17.36	138	76032	53521	110459608
Diabetes mellitus	78.75	17.36	196	75974	99185	110413944
Cholangitis	78.56	17.36	75	76095	16260	110496869
Anxiety	77.51	17.36	74	76096	345004	110168125
Contusion	77.19	17.36	32	76138	233329	110279800
Endocrine disorder	76.85	17.36	29	76141	1095	110512034
C-reactive protein abnormal	76.20	17.36	3	76167	129692	110383437
Silent thyroiditis	75.24	17.36	21	76149	294	110512835
Immune thrombocytopenia	75.22	17.36	85	76085	22409	110490720
Meningitis	74.62	17.36	63	76107	11639	110501490
Hypertension	73.08	17.36	151	76019	509933	110003196
Adrenalitis	72.74	17.36	16	76154	75	110513054
Muscle spasms	70.60	17.36	53	76117	278104	110235025
Hepatic failure	70.39	17.36	150	76020	68589	110444540
Skin toxicity	70.18	17.36	61	76109	11722	110501407
Intracranial tumour haemorrhage	68.26	17.36	23	76147	621	110512508
Pericarditis	67.84	17.36	33	76137	219081	110294048
Bursitis	67.32	17.36	6	76164	129912	110383217
Hypoaesthesia	66.43	17.36	71	76099	314152	110198977
Immune-mediated encephalopathy	65.82	17.36	15	76155	85	110513044
Depression	65.65	17.36	73	76097	317262	110195867
Insomnia	65.16	17.36	92	76078	360498	110152631
Joint range of motion decreased	64.85	17.36	5	76165	121827	110391302
Sleep disorder	64.48	17.36	28	76142	198616	110314513
Gastrooesophageal reflux disease	63.99	17.36	22	76148	179954	110333175
Memory impairment	63.54	17.36	28	76142	196916	110316213
Pericardial effusion	63.43	17.36	129	76041	57088	110456041
Metastases to lung	62.03	17.36	78	76092	22985	110490144
Adverse drug reaction	60.17	17.36	3	76167	105556	110407573
Stress	60.03	17.36	3	76167	105345	110407784
Enterocolitis haemorrhagic	59.14	17.36	31	76139	2573	110510556
Hepatic cytolysis	58.53	17.36	122	76048	54931	110458198
Gastritis	58.27	17.36	120	76050	53579	110459550
Urticaria	57.95	17.36	81	76089	318776	110194353
Loss of personal independence in daily activities	57.53	17.36	16	76154	150004	110363125
Prescribed underdose	57.49	17.36	134	76036	65040	110448089
Thyrotoxic crisis	57.19	17.36	28	76142	2012	110511117
Medication error	57.01	17.36	4	76166	105362	110407767
Inappropriate schedule of product administration	56.75	17.36	35	76135	203602	110309527
Obesity	56.71	17.36	6	76164	113345	110399784
Autoimmune myocarditis	56.41	17.36	20	76150	631	110512498
Suicide attempt	55.73	17.36	4	76166	103390	110409739
Cytomegalovirus enterocolitis	54.23	17.36	28	76142	2253	110510876
Meningoradiculitis	53.81	17.36	15	76155	209	110512920
Road traffic accident	52.93	17.36	6	76164	107392	110405737
Autoimmune neuropathy	52.84	17.36	13	76157	107	110513022
Injection site erythema	52.67	17.36	3	76167	94173	110418956
Immune-mediated oesophagitis	52.08	17.36	12	76158	72	110513057
Agitation	51.69	17.36	8	76162	113043	110400086
Transaminases increased	51.24	17.36	126	76044	63264	110449865
Abdominal pain upper	51.11	17.36	102	76068	349009	110164120
Tri-iodothyronine free decreased	51.06	17.36	17	76153	442	110512687
Lichenoid keratosis	50.98	17.36	39	76131	6263	110506866
Paraesthesia	50.49	17.36	70	76100	276451	110236678
Polymyalgia rheumatica	50.21	17.36	39	76131	6403	110506726
Pituitary enlargement	50.05	17.36	13	76157	136	110512993
Tumour pain	49.97	17.36	29	76141	2938	110510191
Suicidal ideation	49.59	17.36	4	76166	93933	110419196
Injection site reaction	49.32	17.36	3	76167	89067	110424062
Chest pain	48.49	17.36	118	76052	376257	110136872
Haemoglobin decreased	48.45	17.36	60	76110	248667	110264462
Brain oedema	48.19	17.36	81	76089	31017	110482112
Tumour haemorrhage	48.10	17.36	35	76135	5210	110507919
Gait inability	47.91	17.36	17	76153	136359	110376770
Hypercholesterolaemia	47.59	17.36	4	76166	90833	110422296
Cholangitis sclerosing	47.42	17.36	30	76140	3552	110509577
Chronic gastritis	47.13	17.36	35	76135	5376	110507753
Gastrointestinal disorder	46.46	17.36	59	76111	241893	110271236
Pulmonary embolism	46.25	17.36	279	75891	214195	110298934
Rheumatoid arthritis	46.07	17.36	85	76085	299528	110213601
Pancreatitis	45.56	17.36	155	76015	93378	110419751
Autoimmune hypothyroidism	45.42	17.36	16	76154	495	110512634
Wrong technique in product usage process	45.34	17.36	4	76166	87344	110425785
Immune-mediated neuropathy	44.97	17.36	13	76157	208	110512921
Angioedema	44.97	17.36	7	76163	98493	110414636
Fluid retention	44.69	17.36	6	76164	94301	110418828
Pancreatic toxicity	44.14	17.36	11	76159	96	110513033
Incorrect dose administered	43.77	17.36	9	76161	103632	110409497
Embolism	43.67	17.36	55	76115	16234	110496895
Sciatica	43.49	17.36	6	76164	92393	110420736
Palpitations	43.48	17.36	28	76142	159184	110353945
Orbital myositis	43.44	17.36	13	76157	236	110512893
Product use in unapproved indication	43.42	17.36	160	76010	447217	110065912
Pancreatic enzymes increased	43.35	17.36	22	76148	1707	110511422
Pulmonary fibrosis	42.81	17.36	9	76161	102033	110411096
Gait disturbance	42.70	17.36	79	76091	278129	110235000
Heart rate increased	42.52	17.36	23	76147	143811	110369318
Primary adrenal insufficiency	42.30	17.36	16	76154	608	110512521
Pancreatic failure	42.30	17.36	24	76146	2330	110510799
Type 2 diabetes mellitus	42.16	17.36	36	76134	177196	110335933
Arthralgia	41.85	17.36	340	75830	779292	109733837
Bradycardia	41.59	17.36	28	76142	155489	110357640
Prerenal failure	41.45	17.36	30	76140	4429	110508700
Confusional state	41.42	17.36	174	75996	468506	110044623
Giant cell arteritis	41.33	17.36	28	76142	3721	110509408
Drug-induced liver injury	41.21	17.36	178	75992	119889	110393240
Thyroxine free decreased	41.09	17.36	19	76151	1201	110511928
Peripheral venous disease	40.71	17.36	5	76165	84112	110429017
Chest discomfort	40.52	17.36	36	76134	173812	110339317
Dyspepsia	40.51	17.36	43	76127	190922	110322207
Optic neuritis	40.51	17.36	44	76126	11103	110502026
Lower limb fracture	40.36	17.36	3	76167	75345	110437784
Autoimmune lung disease	40.24	17.36	12	76158	215	110512914
Achromotrichia acquired	39.96	17.36	8	76162	21	110513108
Metastases to meninges	39.87	17.36	31	76139	5097	110508032
Sialoadenitis	39.47	17.36	24	76146	2649	110510480
Tremor	39.15	17.36	49	76121	202183	110310946
Exposure via body fluid	39.12	17.36	13	76157	336	110512793
Thrombophlebitis migrans	38.96	17.36	16	76154	758	110512371
Nasal congestion	38.59	17.36	10	76160	98272	110414857
Coma	37.63	17.36	17	76153	117852	110395277
Nephrotic syndrome	37.55	17.36	47	76123	13784	110499345
Heart rate decreased	37.51	17.36	6	76164	82750	110430379
Hypertransaminasaemia	37.34	17.36	63	76107	24192	110488937
Eyelid ptosis	37.33	17.36	46	76124	13281	110499848
Gastrointestinal perforation	37.31	17.36	35	76135	7421	110505708
Capillary leak syndrome	36.71	17.36	29	76141	4879	110508250
Sedation	36.69	17.36	3	76167	69680	110443449
Polyneuropathy	36.46	17.36	73	76097	31939	110481190
Liver injury	36.46	17.36	30	76140	150383	110362746
Immune-mediated cytopenia	36.15	17.36	12	76158	309	110512820
Metastases to liver	35.97	17.36	77	76093	35309	110477820
Musculoskeletal pain	35.79	17.36	44	76126	182979	110330150
Cholecystitis	35.65	17.36	64	76106	25818	110487311
Respiratory failure	35.48	17.36	262	75908	215070	110298059
Demyelinating polyneuropathy	35.30	17.36	21	76149	2228	110510901
Intestinal intraepithelial lymphocytes increased	35.21	17.36	11	76159	232	110512897
Cholestasis	35.08	17.36	111	76059	64407	110448722
Peripheral sensory neuropathy	35.03	17.36	50	76120	16630	110496499
Polymyositis	34.59	17.36	25	76145	3683	110509446
General physical health deterioration	34.58	17.36	446	75724	424849	110088280
Neoplasm malignant	34.55	17.36	78	76092	37065	110476064
Stevens-Johnson syndrome	34.54	17.36	90	76080	46811	110466318
Pulmonary sarcoidosis	34.38	17.36	19	76151	1753	110511376
Amnesia	33.97	17.36	15	76155	105393	110407736
Somnolence	33.95	17.36	99	76071	297350	110215779
Oxygen saturation decreased	33.68	17.36	35	76135	156947	110356182
Primary hypothyroidism	33.56	17.36	11	76159	272	110512857
Oesophagitis	33.33	17.36	66	76104	28649	110484480
Cardiac tamponade	33.25	17.36	40	76130	11267	110501862
Metastases to lymph nodes	32.96	17.36	46	76124	14986	110498143
Influenza	32.70	17.36	41	76129	169060	110344069
Blood corticotrophin increased	32.54	17.36	11	76159	300	110512829
Blood corticotrophin abnormal	32.50	17.36	8	76162	66	110513063
Hypogonadism	32.29	17.36	19	76151	1975	110511154
Osteoporosis	32.12	17.36	10	76160	87142	110425987
Cardiac failure congestive	32.02	17.36	34	76136	150966	110362163
Melanoma recurrent	31.87	17.36	11	76159	320	110512809
Blood pressure systolic increased	31.54	17.36	9	76161	82982	110430147
Blood glucose increased	31.40	17.36	27	76143	132469	110380660
Pneumonia bacterial	31.25	17.36	61	76109	26200	110486929
Rhinorrhoea	30.96	17.36	16	76154	102650	110410479
Spermatogenesis abnormal	30.78	17.36	6	76164	13	110513116
Swollen tongue	30.70	17.36	3	76167	60359	110452770
Therapeutic response decreased	30.68	17.36	14	76156	96485	110416644
Sudden death	30.67	17.36	58	76112	24337	110488792
Cancer pain	30.51	17.36	30	76140	6742	110506387
Hallucination	30.30	17.36	16	76154	101416	110411713
Underdose	30.21	17.36	4	76166	63550	110449579
Joint stiffness	30.20	17.36	5	76165	67238	110445891
Neurofibrosarcoma	30.11	17.36	10	76160	258	110512871
Cryptitis	30.02	17.36	11	76159	382	110512747
Apoptosis	29.86	17.36	13	76157	713	110512416
Hyperhidrosis	29.80	17.36	52	76118	187246	110325883
Tumour associated fever	29.78	17.36	15	76155	1146	110511983
Microvillous inclusion disease	29.71	17.36	10	76160	269	110512860
Acquired tracheo-oesophageal fistula	29.59	17.36	9	76161	173	110512956
Infusion related reaction	29.22	17.36	149	76021	381013	110132116
Pleurocutaneous fistula	29.20	17.36	7	76163	51	110513078
Hepatic enzyme increased	29.04	17.36	118	76052	320774	110192355
Tumour lysis syndrome	29.01	17.36	65	76105	30736	110482393
Pulmonary sepsis	28.79	17.36	26	76144	5252	110507877
Pregnancy on contraceptive	28.75	17.36	14	76156	994	110512135
Performance status decreased	28.73	17.36	30	76140	7236	110505893
Balance disorder	28.55	17.36	23	76147	116537	110396592
Myelitis	28.47	17.36	21	76149	3192	110509937
Autoimmune uveitis	28.46	17.36	6	76164	22	110513107
Hypokalaemia	28.37	17.36	219	75951	182229	110330900
Sarcoid-like reaction	28.19	17.36	10	76160	316	110512813
Unresponsive to stimuli	28.08	17.36	5	76165	63785	110449344
Septic shock	27.87	17.36	195	75975	157333	110355796
Glomerulonephritis minimal lesion	27.70	17.36	14	76156	1077	110512052
Electrocardiogram QT prolonged	27.32	17.36	21	76149	108939	110404190
Burning sensation	27.25	17.36	7	76163	69205	110443924
Headache	26.15	17.36	439	75731	881938	109631191
Loss of consciousness	25.69	17.36	61	76109	196245	110316884
Atrioventricular block complete	25.56	17.36	48	76122	20034	110493095
Probiotic therapy	25.51	17.36	8	76162	171	110512958
Autoimmune retinopathy	25.49	17.36	6	76164	40	110513089
Night sweats	25.37	17.36	33	76137	133950	110379179
Accidental overdose	25.28	17.36	3	76167	51831	110461298
Lichen planus	25.19	17.36	20	76150	3390	110509739
Aplasia pure red cell	25.13	17.36	32	76138	9546	110503583
Polyarthritis	24.98	17.36	46	76124	18917	110494212
White blood cell count decreased	24.98	17.36	78	76092	229312	110283817
Wound infection	24.95	17.36	18	76152	96447	110416682
Cortisol increased	24.93	17.36	11	76159	623	110512506
Bile duct stenosis	24.87	17.36	18	76152	2658	110510471
Blood creatine phosphokinase increased	24.81	17.36	108	76062	72969	110440160
Diarrhoea haemorrhagic	24.58	17.36	41	76129	15598	110497531
Physical deconditioning	24.54	17.36	20	76150	3517	110509612
Inflammation	24.54	17.36	61	76109	193177	110319952
Lactic acidosis	24.42	17.36	17	76153	92794	110420335
Multiple sclerosis relapse	24.27	17.36	3	76167	50237	110462892
Gastrointestinal toxicity	24.27	17.36	34	76136	11114	110502015
Myelitis transverse	24.27	17.36	17	76153	2384	110510745
Peripheral motor neuropathy	24.02	17.36	21	76149	4065	110509064
Metastases to bone	23.93	17.36	61	76109	31311	110481818
Nephrolithiasis	23.69	17.36	8	76162	66204	110446925
Plasma cell myeloma	23.59	17.36	7	76163	62929	110450200
Blood bilirubin increased	23.34	17.36	109	76061	75863	110437266
Aggression	23.29	17.36	6	76164	59204	110453925
Encephalopathy	23.24	17.36	114	76056	80941	110432188
Autoimmune cholangitis	23.16	17.36	6	76164	62	110513067
Anaemia	22.83	17.36	515	75655	546571	109966558
Cutaneous sarcoidosis	22.82	17.36	10	76160	557	110512572
Infection	22.72	17.36	151	76019	362049	110151080
Eosinophilic fasciitis	22.72	17.36	9	76161	388	110512741
Altered state of consciousness	22.58	17.36	89	76081	57537	110455592
Retinopathy	22.57	17.36	21	76149	4408	110508721
General physical condition abnormal	22.56	17.36	27	76143	7563	110505566
Troponin I increased	22.44	17.36	23	76147	5429	110507700
Feeling hot	22.29	17.36	18	76152	91088	110422041
Serous retinopathy	22.14	17.36	8	76162	267	110512862
Throat irritation	21.90	17.36	5	76165	53547	110459582
Tumour embolism	21.86	17.36	8	76162	277	110512852
Myocardial infarction	21.86	17.36	64	76106	192019	110321110
Melanosis	21.84	17.36	6	76164	79	110513050
Blood thyroid stimulating hormone increased	21.72	17.36	34	76136	12267	110500862
Secondary hypogonadism	21.69	17.36	11	76159	852	110512277
Lymphangiosis carcinomatosa	21.49	17.36	16	76154	2466	110510663
VIth nerve paralysis	21.42	17.36	14	76156	1753	110511376
Bronchitis	21.19	17.36	48	76122	156984	110356145
Toxic epidermal necrolysis	20.94	17.36	86	76084	56641	110456488
Respiratory arrest	20.93	17.36	7	76163	58292	110454837
Renal disorder	20.68	17.36	78	76092	49401	110463728
Haematocrit decreased	20.39	17.36	10	76160	66107	110447022
Multiple organ dysfunction syndrome	20.29	17.36	176	75994	151534	110361595
Red blood cell count decreased	20.28	17.36	10	76160	65913	110447216
Metastases to adrenals	20.16	17.36	13	76157	1590	110511539
Pancreatic atrophy	20.01	17.36	10	76160	751	110512378
Cortisol abnormal	19.84	17.36	6	76164	113	110513016
Drug dependence	19.81	17.36	5	76165	50015	110463114
Sarcoidosis	19.80	17.36	33	76137	12546	110500583
Localised infection	19.78	17.36	3	76167	43045	110470084
Tumour necrosis	19.54	17.36	15	76155	2421	110510708
Tachycardia	19.47	17.36	85	76085	226560	110286569
Limbic encephalitis	19.44	17.36	10	76160	798	110512331
Cytomegalovirus colitis	19.18	17.36	24	76146	7037	110506092
Jejunal ulcer	19.03	17.36	7	76163	246	110512883
Rash pruritic	18.89	17.36	124	76046	97945	110415184
Retinal melanoma	18.84	17.36	3	76167	0	110513129
Hypoalbuminaemia	18.73	17.36	53	76117	28921	110484208
Product prescribing error	18.72	17.36	6	76164	51325	110461804
Immune-mediated cholestasis	18.70	17.36	5	76165	59	110513070
Surgery	18.69	17.36	3	76167	41280	110471849
Chylothorax	18.68	17.36	11	76159	1145	110511984
Upper respiratory tract infection	18.66	17.36	39	76131	131289	110381840
Blood lactate dehydrogenase increased	18.62	17.36	70	76100	44264	110468865
Haemolytic anaemia	18.43	17.36	43	76127	20877	110492252
Autoimmune thyroid disorder	18.26	17.36	5	76165	65	110513064
Swelling face	18.25	17.36	22	76148	92299	110420830
Rheumatic disorder	18.25	17.36	17	76153	3574	110509555
Extraocular muscle disorder	18.22	17.36	8	76162	448	110512681
Granulomatous lymphadenitis	18.20	17.36	8	76162	449	110512680
Therapy non-responder	18.20	17.36	52	76118	157255	110355874
White blood cell count increased	18.18	17.36	24	76146	96818	110416311
Inappropriate antidiuretic hormone secretion	18.18	17.36	58	76112	33793	110479336
Erosive duodenitis	18.14	17.36	14	76156	2277	110510852
Thyroiditis subacute	18.13	17.36	8	76162	453	110512676
Metastases to skin	18.10	17.36	14	76156	2285	110510844
Diabetic ketosis	18.06	17.36	10	76160	926	110512203
Acute motor axonal neuropathy	18.06	17.36	6	76164	155	110512974
Illness	17.99	17.36	18	76152	82153	110430976
Propionibacterium infection	17.96	17.36	7	76163	289	110512840
Parvovirus infection	17.91	17.36	10	76160	941	110512188
Stomatitis	17.79	17.36	111	76059	270131	110242998
Flushing	17.65	17.36	28	76142	104708	110408421
Head injury	17.62	17.36	4	76166	43013	110470116
Radiation skin injury	17.54	17.36	12	76158	1620	110511509
Epistaxis	17.47	17.36	40	76130	130332	110382797
Toxic skin eruption	17.47	17.36	50	76120	27465	110485664
Abdominal distension	17.37	17.36	62	76108	175041	110338088

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01FX04	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES Other monoclonal antibodies and antibody drug conjugates
MeSH PA	D000074322	Antineoplastic Agents, Immunological
MeSH PA	D000082082	Immune Checkpoint Inhibitors
MeSH PA	D000970	Antineoplastic Agents
FDA PE	N0000182157	Increased T Lymphocyte Activation
FDA MoA	N0000182634	CTLA-4-directed Antibody Interactions
FDA EPC	N0000182635	CTLA-4-directed Blocking Antibody
CHEBI has role	CHEBI:22587	antiviral agent
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:64946	anti-HIV agent

Related Drugs by ATC class:

L01FX Other monoclonal antibodies and antibody drug conjugates 29 drugs

amivantamab belantamab mafodotin blinatumomab brentuximab vedotin catumaxomab datopotamab deruxtecan elotuzumab elranatamab enfortumab vedotin epcoritamab gemtuzumab ozogamicin glofitamab show all 29 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Unresectable advanced or recurrent malignant pleural mesothelioma	indication	254645002	DOID:7474
Unresectable advanced or recurrent esophageal cancer	indication	363402007
Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation	indication	427038005
Metastatic malignant melanoma	indication	443493003
Renal cell carcinoma	indication	702391001	DOID:4450
Microsatellite instability-high colorectal cancer	indication	737058005
High grade squamous intraepithelial neoplasia of esophagus	indication	1197288009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Cytotoxic T-lymphocyte protein 4	Surface antigen	P16410	CTLA4_HUMAN		Kd	8.07		IUPHAR	DRUG LABEL

External reference:

ID	Source
D04603	KEGG_DRUG
4030653	VUID
N0000182641	NUI
4030653	VANDF
CHEBI:231679	CHEBI
CHEMBL1789844	ChEMBL_ID
6888	IUPHAR_LIGAND_ID
DB06186	DRUGBANK_ID
1094833	RXNORM
180596	MMSL
27014	MMSL
d07565	MMSL
013688	NDDF
697995005	SNOMEDCT_US
704649006	SNOMEDCT_US
C1367202	UMLSCUI
D000074324	MESH_DESCRIPTOR_UI
8568	INN_ID
6T8C155666	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
YERVOY	HUMAN PRESCRIPTION DRUG LABEL	1	0003-2327	INJECTION	5 mg	INTRAVENOUS	BLA	26 sections
YERVOY	HUMAN PRESCRIPTION DRUG LABEL	1	0003-2328	INJECTION	5 mg	INTRAVENOUS	BLA	26 sections

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

ipilimumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: